文献速递腹部MR

如何鉴别伴有环状动脉期高强化的混合型肝细胞癌-胆管癌与肝内胆管癌?

How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?
PubMed 文献 · Abdom Radiol (NY) · 2024-03-01

本研究纳入病理证实的70例混合型肝细胞癌-胆管癌(cHCC-CCA)和74例肝内胆管癌(iCCA)患者,对比其MRI特征。多因素分析显示AFP>20 ng/ml、强化包膜和镶嵌架构是cHCC-CCA的独立危险因素,肝包膜回缩是iCCA的独立预测因素;联合AFP与强化包膜和/或镶嵌架构可提高鉴别敏感度。

要点

  • 伴有环状动脉期高强化的肝脏病变,若出现强化包膜或镶嵌架构,需考虑混合型肝细胞癌-胆管癌。
  • 肝包膜回缩是肝内胆管癌的独立预测因素(OR=0.091)。
  • AFP>20 ng/ml联合强化包膜和/或镶嵌架构可提高鉴别cHCC-CCA的敏感度。

核心结论

  • 联合AFP升高与MRI特征(强化包膜和镶嵌架构)有助于术前鉴别伴有环状动脉期高强化的cHCC-CCA与iCCA。

研究设计与样本

  • 回顾性纳入病理证实的70例cHCC-CCA和74例iCCA患者,对比临床病理数据及MRI特征,并行单因素和多因素回归分析及敏感度、特异度、AUC分析。

关键影像表现/征象

  • 强化包膜在cHCC-CCA中的OR=7.252(p=0.001),为独立危险因素。
  • 镶嵌架构在cHCC-CCA中的OR=32.732(p<0.001),为独立危险因素。
  • 肝包膜回缩在iCCA中的OR=0.091(p<0.001),为独立预测因素。

诊断标准与关键数值

  • AFP>20 ng/ml鉴别cHCC-CCA的OR=5.824(p=0.006)。
  • AFP>20 ng/ml联合强化包膜鉴别cHCC-CCA的敏感度为96.7%,高于对照的79.2%(p<0.001)。
  • AFP>20 ng/ml联合镶嵌架构鉴别cHCC-CCA的敏感度为96.4%,高于对照的94.7%(p<0.001)。

临床应用与阅片要点

  • 对伴有环状动脉期高强化的肝脏病变,阅片时应评估强化包膜、镶嵌架构及肝包膜回缩。
  • 结合AFP>20 ng/ml与强化包膜和/或镶嵌架构,可提高鉴别cHCC-CCA与iCCA的敏感度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To analyze and compare the differences in MRI features between combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) and intrahepatic cholangiocarcinoma (iCCA) with arterial phase peripheral enhancement, so as to provide valuable references for preoperative differential diagnosis.

METHODS: Seventy cHCC-CCA patients and 74 iCCA patients confirmed by pathology were included in this study. Their contrast-enhanced MRI showed rim arterial phase hyperenhancement (Rim APHE). The differences of clinicopathological data and MRI features between cHCC-CCA and iCCA were compared. Then, the sensitivity, specificity, and area under curve (AUC) were also analyzed and compared.

RESULTS: Seventy cHCC-CCA patients (mean age, 55.7 ± 10.6 years) and 74 iCCA patients (mean age, 61.1 ± 10.5 years) were evaluated. In this study, univariable and multivariable regression analysis showed that AFP > 20 ng/ml (OR = 5.824, p = 0.006), enhancing capsule (OR = 7.252, p = 0.001), and mosaic architecture (OR = 32.732, p < 0.001) were independent risk factors of cHCC-CCA with Rim APHE. However, only hepatic capsule retraction (OR = 0.091, p < 0.001) was an independent predictor of iCCA. In addition, combining AFP > 20 ng/ml with enhancing capsule (96.7% vs. 79.2%, p < 0.001) and/or mosaic architecture (96.4% vs. 94.7%, p < 0.001) can improve the sensitivity of differentiating cHCC-CCA (vs. iCCA) with Rim APHE.

CONCLUSION: The combination of elevated AFP and MRI features, such as enhancing capsule and mosaic architecture, will help in preoperative differential diagnosis of cHCC-CCA and iCCA with Rim APHE.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Zhou C, Huang P, Wu F, et al. How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement? Abdom Radiol (NY). 2024. PMID: 38427077. doi:10.1007/s00261-024-04194-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。